Navigation Links
New Interventional Radiology Treatment Shows Hope for People With Complications from Bone Marrow, Stem Cell Transplants
Date:3/18/2008

High-Dose Steroids Delivered Directly to the Organ Successfully Treats

Graft-Versus-Host Disease

WASHINGTON, March 18 /PRNewswire-USNewswire/ -- The standard treatment to treat graft-versus-host disease (GVHD) after bone marrow or cord blood transplant is intravenous (IV) steroids that alter the immune response; however, it is not always effective and failure results in very high mortality. In a study released today, 15 patients who failed standard treatment were given a high dose of steroids directly to the affected organ. By delivering the steroids via catheter to the arteries that are supplying the organs affected by GVHD, a much higher, more effective dose can be given because the rest of the body is spared from the steroid's side effects.

"Overall, fewer than 30 percent of patients with steroid-resistant GVHD respond completely or partially to the standard IV treatment, and their chance of living one year is 15 percent or less. This interventional radiology treatment can be life-saving for these people," said Joshua L. Weintraub, M.D., chief of the Division of Vascular and Interventional Radiology at Mount Sinai Medical Center in New York City.

According to Weintraub, there were no immediate drug or procedure-related complications, and the treatment appears to be safe and effective in combating GVHD -- with about 40 percent of the patients showing complete response to the intra-arterial treatment at less than a year follow-up. The study was presented during the Society of Interventional Radiology's 33rd Annual Scientific Meeting in Washington, D.C.

GVHD is a common complication of an allogeneic bone marrow transplant (one using blood-forming cells donated by a family member or unrelated donor) or cord blood transplant. With GVHD, the immune cells from the donated marrow or cord blood (the graft) attack the body of the transplant patient (the host). GVHD, which can be mild to life-threatening, can affect many different parts of the body, particularly the skin, liver and intestines. In this study the affected organs were the liver and small and large bowels.

Studies from the 1990s show that steroid resistance is common -- 80 percent of people fail to have a sustained, complete response rate or only have a partial response, which means the immune cells are still attacking the organ to varying degrees. "Until now, there has been no good therapy for steroid-resistant patients with GVHD. This small study -- the first of its kind in the United States--shows a new, viable option; however, larger studies with longer follow-up results are needed," added Weintraub.

Abstract 187, "Intra-arterial Steroid Injection Therapy for Systemic Steroid Resistant Graft-Versus-Host Disease," can be found at http://www.SIRmeeting.org.

About Graft-Versus-Host Disease

Graft-versus-host disease (GVHD) is a common side effect of an allogeneic bone marrow transplant (one using blood-forming cells donated by a family member or unrelated donor) or cord blood transplant. The differences between a donor's marrow and recipient's tissues often cause T cells (a type of white blood cell) from the donor's marrow to recognize the recipient's body tissues as foreign, according to the National Institutes of Health. GVHD is the term used when a donor's immune cells attacks the recipient's body -- causing damage. Acute GVHD starts within three months after transplant, while chronic GVHD begins more than three months after transplant (and can last as long as three years). NIH notes that rates of GVHD vary from 30-40 percent for related donors and recipients to 60-80 percent for unrelated donors and recipients. Following a bone marrow transplant, the recipient is prescribed drugs that suppress the immune system to help with reducing the chances or severity of GVHD.

Bone marrow transplants are usually reserved for individuals with life-threatening diseases of the blood, bone marrow or certain types of cancer.

About the Society of Interventional Radiology

Interventional radiologists are physicians who specialize in minimally invasive, targeted treatments. They offer the most in-depth knowledge of the least invasive treatments available coupled with diagnostic and clinical experience across all specialties. They use X-ray, MRI and other imaging to advance a catheter in the body, usually in an artery, to treat at the source of the disease internally. As the inventors of angioplasty and the catheter-delivered stent, which were first used in the legs to treat peripheral arterial disease, interventional radiologists pioneered minimally invasive modern medicine.

Today many conditions that once required surgery can be treated less invasively by interventional radiologists. Interventional radiology treatments offer less risk, less pain and less recovery time compared to open surgery. Visit http://www.SIRweb.org.

Local interviews are available by contacting SIR's communications department at mverrillo@SIRweb.org.


'/>"/>
SOURCE Society of Interventional Radiology
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. SCAI and ACC announce new interventional cardiology meeting
2. Gorilla Receives State-Of-The-Art Treatment for Uterine Fibroids from Interventional Radiologists
3. Stereotaxis Showcases Interventional Cardiology Capabilities of Niobe Magnetic Navigation System
4. Siemens Introduces Its New Generation of Artis Interventional Imaging Systems
5. SCAI Announces New Program to Support Interventional Cardiology Training Fellowships
6. Register Now for Interventional Radiology Meeting Press Conferences
7. AIUM CEO named among most influential in radiology
8. Abaxis Announces New Waived Kidney Check Panel Exclusively for Imaging and Radiology Centers
9. NightHawk Radiology Holdings, Inc. Announces Date for Third Quarter Earnings Conference Call
10. Franklin & Seidelmann Enters Full-Service Teleradiology Market with Acquisition of Apex Radiology
11. Radiology Ltd. Chooses AMICAS as End-to-End Solutions Provider
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van ... Wellness at Work award to iHire in recognition of their exemplary accomplishments in worksite ... 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum ...
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... Texas (PRWEB) , ... June 24, 2016 , ... ... International Conference and Scientific Sessions in Dallas that it will receive two significant ... of the grants came as PHA marked its 25th anniversary by recognizing patients, ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)...  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported ... required to build a strong and stable market for ... on the OTC Markets-pink current trading platform. ... are seeing an anomaly in market trading activities that ... the Company, but shareholders and market players as well. ...
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... ALEXANDRIA, Va. , June 24, 2016 ... a set of recommendations that would allow ... information (HCEI) with entities that make formulary and coverage ... determine the "value" of new medicines. The ... that does not appear on the drug label, a ...
Breaking Medicine Technology: